Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

First Tracks Biotherapeutics at Jefferies: celiac data lifts outlook

First Tracks Biotherapeutics at Jefferies: celiac data lifts outlook

On Monday, November 16, 2026, First Tracks Biotherapeutics (TRAX) shared new clinical data for its lead drug ANB033 at the Jefferies Global Healthcare Conference. The company's focus was on celiac disease, for which there are currently no approved treatments. ANB033 demonstrated strong activity in a gluten challenge study, showing significant improvement in villus height to crypt depth ratio, lower intraepithelial lymphocytes, and no symptom increase during gluten exposure.

The drug works by blocking the signaling of IL-2 and IL-15 pathways, which are involved in celiac disease biology. ANB033 is a CD122 antagonist designed to affect both acute symptom initiation and long-term tissue injury triggered by gluten exposure. First Tracks reported $350 million in cash, which they estimate will keep the company operational through the second half of 2029.

The company plans to initiate late-stage celiac trials in 2027 after discussions with regulators. Additionally, they are testing ANB033 for eosinophilic esophagitis, while advancing other programs in vitiligo, BDCA2 depletion and PD-1 depletion. The company sees substantial market potential in both celiac disease - a disease with no approved therapy - and EoE, where Dupixent is already generating over $3 billion in annual U.S. sales.

CEO Dan Faga highlighted the statistical significance and compelling nature of the celiac trial data, describing it as a crucial step for a disease area with no current drug treatments. ANB033 showed no increase in symptoms during the 14-day gluten challenge, while placebo patients experienced significant symptom worsening. About half of placebo patients used symptomatic medication, but the treatment difference remained evident.

The Phase II Cohort 1 study included 32 patients, with 17 receiving ANB033 and 15 on placebo. All patients had a baseline villus height to crypt depth ratio above 2.0, indicating moderate to mild disease. The primary endpoint measured villus height to crypt depth ratio at week 6 biopsy, with ANB033 achieving a statistically significant 0.49 delta compared to placebo.

ANB033 also resulted in a 98% reduction in intraepithelial lymphocytes during the gluten challenge, a first for any company in these conditions. The drug was well tolerated, with no serious or severe adverse events reported. Additionally, First Tracks is conducting a second celiac study (Cohort 2) to evaluate healing rather than prevention of worsening after gluten exposure.

This study has completed enrollment, with 50 patients receiving the same three-dose schedule at weeks 0, 2, and 4, but without a gluten challenge. The primary endpoint is villus height to crypt depth healing at week 12, with results expected in the first quarter of 2027.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →